Although the drug requires no CYP2C9 genotyping or first-dose observation, an up-titration scheme should be used due to the risk of transient cardiac conduction issues.
Disease-modifying therapies used to treat several immune-mediated disorders in neurology may make patients more susceptible to the novel coronavirus.
The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.
The novel B-cell therapy has been assigned a PDUFA date of June 2020.
The latest generic entry comes on the heels of a new report from ICER, which published a list of prescription drugs that had substantial price increases in 2017 and 2018 without what they consider to be new supporting evidence.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fred Rincon, MD, MSc.
New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.
With a growing emphasis on early detection and intervention, the American Academy of Neurology (AAN) has published a new set of quality measurements that recommend that physicians screen adults 65 and older on an annual basis for thinking
The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.
Rodney Allan Radtke, MD, professor of neurology at Duke University School of Medicine in Durham, North Carolina, discussed some of the new therapeutic options available to help improve tolerance and adherence challenges that clinicians commonly face in epilepsy practice.